Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Killestein

Showing results (21-30 of 89) with videos related to

Pageof 9
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|August 3, 2007
[Immunomodulatory therapy in multiple sclerosis]B M J Uitdehaag, B Jelles, J Killestein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 7, 2000
Quality of life during the first 6 months of interferon-beta treatment in patients with MSJ H Arnoldus, J Killestein, L E Pfennings, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 5, 2008
Serum homocysteine levels in relation to clinical progression in multiple sclerosisC E Teunissen, J Killestein, J J Kragt, et al.
Neurology|September 26, 2001
TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MSJ Killestein, N F Kalkers, J F Meilof, et al.
Neurology|March 17, 2010
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatmentJ Killestein, M L van der Meer, J C Regelink, et al.
European Journal of Neurology|June 3, 2009
Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosisL F van der Voort, A Visser, D L Knol, et al.
Annals of Neurology|February 9, 2000
Intracellular adhesion molecule-1 polymorphisms and genetic susceptibility to multiple sclerosis: additional data and meta-analysisJ Killestein, H M Schrijver, J B Crusius, et al.
Multiple Sclerosis and Related Disorders|November 16, 2019
Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision makingC E P van Munster, L Kaya, K H Lam, et al.
International Journal of MS Care|July 20, 2023
Rest-Activity Rhythm, Pain, and Motor Activity in Multiple SclerosisRogier J Scherder, M J van Dorp, A J Prins, et al.
Journal of Neuroimmunology|August 11, 2001
Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cellsJ Killestein, M H Rep, F Barkhof, et al.
Pageof 9

Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Nederlands Tijdschrift Voor Geneeskunde|August 3, 2007
[Immunomodulatory therapy in multiple sclerosis]B M J Uitdehaag, B Jelles, J Killestein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 7, 2000
Quality of life during the first 6 months of interferon-beta treatment in patients with MSJ H Arnoldus, J Killestein, L E Pfennings, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 5, 2008
Serum homocysteine levels in relation to clinical progression in multiple sclerosisC E Teunissen, J Killestein, J J Kragt, et al.
Neurology|September 26, 2001
TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MSJ Killestein, N F Kalkers, J F Meilof, et al.
Neurology|March 17, 2010
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatmentJ Killestein, M L van der Meer, J C Regelink, et al.
European Journal of Neurology|June 3, 2009
Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosisL F van der Voort, A Visser, D L Knol, et al.
Annals of Neurology|February 9, 2000
Intracellular adhesion molecule-1 polymorphisms and genetic susceptibility to multiple sclerosis: additional data and meta-analysisJ Killestein, H M Schrijver, J B Crusius, et al.
Multiple Sclerosis and Related Disorders|November 16, 2019
Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision makingC E P van Munster, L Kaya, K H Lam, et al.
International Journal of MS Care|July 20, 2023
Rest-Activity Rhythm, Pain, and Motor Activity in Multiple SclerosisRogier J Scherder, M J van Dorp, A J Prins, et al.
Journal of Neuroimmunology|August 11, 2001
Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cellsJ Killestein, M H Rep, F Barkhof, et al.
Pageof 9